NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Is Microdosing Just a Placebo? What Placebo-Controlled Studies Show
Placebo-controlled studies show that microdoses measurably change the brain and body, but so far they find few consistent improvements in mood or wellbeing beyond placebo. Surveys and personal reports are far more pos...
Horizons 2026: New Medicines for an Old System
As pharmaceutical companies and mainstream medicine increasingly embrace psychedelic therapies, attendees at the nineteenth Horizons conference examined barriers to access and the broader paradox of how psychedelics c...
American Trickster: The Hidden Lives of Carlos Castaneda
A new biography by Ru Marshall examines the long shadow that hoaxer Carlos Castaneda cast on psychedelics and new age spirituality. The post American Trickster: The Hidden Lives of Carlos Castaneda first appeared on L...
FDA Holds Historic Public Hearing on Psychedelic Therapies
A highly anticipated public hearing at the FDA focused on questions about credentialing providers of psychedelic-assisted therapies, patient safety, data standardization, and equitable access to emerging therapies. Th...
Psychedelic Policy Briefing 8.21.26
Resilient Pharmaceuticals (formerly Lykos Therapeutics and MAPS PBC), reportedly resubmitted their once-rejected New Drug Application (NDA) for MDMA-assisted therapy for PTSD to the FDA, triggering a fresh review cycl...
Microdosing for Anxiety: What the Evidence Shows, and Where It Doesn’t
Microdosing for anxiety looks encouraging in open-label surveys and far less convincing under placebo control. What facilitators need to know about the evidence, the protocols, the contraindications, and the backfire ...
Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High
Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On August 5, 2026, the...
Psychedelic Policy Briefing
In this week's psychedelic policy briefing, investigative journalist Jack Gorsline unpacks a wave of state and federal initiatives aimed at expanding alternative therapies for veterans and those battling addiction. Th...
Have You Had Difficulties After a Trip? The Emory Center for Psychedelics and Spirituality Wants to Hear From You
An international research consortium including Brown University, the University of Melbourne, the University of North Texas, and Dr. Roman Palitsky of Emory University is seeking participants for the Post-Psychedelic ...
MAPS Announces Agreement with UAB
MAPS can now share we have finalized a clinical trial agreement with the University of Alabama, Birmingham, making UAB the first official site for the MJP2 study of inhaled cannabis in the treatment of PTSD in U.S. mi...
FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.
For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found them...
Clinical-Trial Cannabis and Placebo has Been Shipped
Following receipt of an import permit from Health Canada, RTI, which is the contracted licensed distributor for NDSP, successfully shipped the placebo cannabis to Aqualitas, the Canadian licensed cannabis producer for...
Approval Is Not Access: A Postcard From Psychedelic Europe
At ICPR 2026 at the historic city ofin Haarlem in the Netherlands, the companies racing to turn psychedelics into approved medicines were nowhere to be found, leaving a hall full of researchers, clinicians, and one re...
Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series
In a study on iboga microdosing, in all three cases, participants reported better sleep, improved mood regulation, and a greater ability to return to daily activities.
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
Repeated microdosing of LSD (8 to 20 μg) may help improve daily mood, specifically increasing feelings of connection, creativity, and energy in people with major depressive disorder.